Full metadata record
DC Field | Value | Language |
---|---|---|
dc.creator | Aznar, M.A. (María Ángela) | - |
dc.creator | Planelles, M. (María) | - |
dc.creator | Perez-Olivares, M. (Mercedes) | - |
dc.creator | Molina, C. (Carmen) | - |
dc.creator | Garasa, S. (Saray) | - |
dc.creator | Etxeberria, I. (Iñaki) | - |
dc.creator | Perez, G. (Guiomar) | - |
dc.creator | Rodriguez, I. (Inmaculada) | - |
dc.creator | Bolaños, E. (Elixabet) | - |
dc.creator | Lopez-Casas, P. (Pedro) | - |
dc.creator | Rodriguez-Ruiz, M.E. (María Esperanza) | - |
dc.creator | Perez-Gracia, J.L. (Jose Luis) | - |
dc.creator | Marquez-Rodas, I. (Iván) | - |
dc.creator | Teijeira, A. (Álvaro) | - |
dc.creator | Quintero, M. (Marisol) | - |
dc.creator | Melero, I. (Ignacio) | - |
dc.date.accessioned | 2019-07-10T06:32:37Z | - |
dc.date.available | 2019-07-10T06:32:37Z | - |
dc.date.issued | 2019 | - |
dc.identifier.citation | Aznar, M.A. (María Ángela); Planelles, M. (María); Perez-Olivares, M. (Mercedes); et al. "Immunotherapeutic effects of intratumoral nanoplexed poly I:C". Journal for ImmunoTherapy of Cancer. 7 (116), 2019, 1 - 16 | es_ES |
dc.identifier.issn | 2051-1426 | - |
dc.identifier.uri | https://hdl.handle.net/10171/57958 | - |
dc.description.abstract | Poly I:C is a powerful immune adjuvant as a result of its agonist activities on TLR-3, MDA5 and RIG-I. BO-112 is a nanoplexed formulation of Poly I:C complexed with polyethylenimine that causes tumor cell apoptosis showing immunogenic cell death features and which upon intratumoral release results in more prominent tumor infiltration by T lymphocytes. Intratumoral treatment with BO-112 of subcutaneous tumors derived from MC38, 4 T1 and B16- F10 leads to remarkable local disease control dependent on type-1 interferon and gamma-interferon. Some degree of control of non-injected tumor lesions following BO-112 intratumoral treatment was found in mice bearing bilateral B16-OVA melanomas, an activity which was enhanced with co-treatment with systemic anti-CD137 and anti-PD-L1 mAbs. More abundant CD8+ T lymphocytes were found in B16-OVA tumor-draining lymph nodes and in the tumor microenvironment following intratumoral BO-112 treatment, with enhanced numbers of tumor antigen-specific cytotoxic T lymphocytes. Genome-wide transcriptome analyses of injected tumor lesions were consistent with a marked upregulation of the type-I interferon pathway. Inspired by these data, intratumorally delivered BO-112 is being tested in cancer patients (NCT02828098). | es_ES |
dc.description.sponsorship | This study was financially supported by grants from MINECO (SAF2014–52361-R, FEDER/MICIU-AEI/SAF2017–83267-C2–1-R) to IM and JL-G. IM was also funded by European Commission VII Framework and Horizon 2020 programs (IACT FP7/ 2007-2013 grant agreement 602262 and PROCROP grant agreement 635122 respectively), Fundación de la Asociación Española Contra el Cán- cer (AECC), Fundación BBVA. Bioncotech received funding from CDTI (IDI-20170635) to support this project. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | BMC | es_ES |
dc.relation | info:eu-repo/grantAgreement/EC/FP7/602262/EU | - |
dc.relation | info:eu-repo/grantAgreement/EC/H2020/635122/EU | - |
dc.rights | info:eu-repo/semantics/openAccess | es_ES |
dc.subject | BO-112 | es_ES |
dc.subject | Intratumoral immunotherapy | es_ES |
dc.subject | Nanoplexed poly I:C | es_ES |
dc.title | Immunotherapeutic effects of intratumoral nanoplexed poly I:C | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.description.note | This is an open access article distributed under the Creative Commons: Atribution License (cc BY) | es_ES |
dc.identifier.doi | 10.1186/s40425-019-0568-2 | - |
dc.identifier.doi | https://doi.org/10.1186/s40425-019-0568-2 | es_ES |
Files in This Item:
Statistics and impact
Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.